



Corporate Presentation
November 2008

Disclosure Statement

- All drawings, artwork, and texts are the exclusive property of Alapis S.A. The partial or total duplication, copy or publication of the contents of this publication by any medium (mechanical, electronic, photocopy, recording, photography etc) is forbidden according to the standing copyright Law (Law 100/75 and Law 2121/1993) relevant instruction and disclaimers by the EU and the International Law. Any use of material included in this publication must be done with the written permission of Alapis SA
- The logo of Alapis SA is the exclusive property of Alapis SA. Any use, copying or distortion of the logo is forbidden without written permission by the company. The contents and visual material included in this publication are the property of Alapis SA or third parties from which the company has received all appropriate licences
- Copyright refers to all graphics and texts of the present publication
- The facts included in the present document have been acquired by valid sources. It is considered self-evident and granted that Alapis S.A. does not guarantee their accuracy and endurance through time. Respectively, Alapis S.A. bears no responsibility to any investment actions that may take place on the basis of the estimates published here. This is not an offer of invitation for purchase or registration of market shares of any kind. Finally, the information included in this publication is subject to renewal, completion, review or modification by Alapis S.A. The information may be significantly modified without any liability for prior update on behalf of Alapis S.A.

Agenda


- **Business overview**
- **Strategy**
- **Health Division**
 - Pharmaceuticals
 - Medical Devices & Equipment
 - Veterinary Pharmaceuticals & Pet Accessories
- **Non-Health Division**
 - Cosmetics & Detergents
 - Organic products
- **Financials**
- **Appendix**

Overview of Alapis

- **Leading consolidator in the Greek generics market**
- Formed in February 2007 from the merger of EBIK, Elpharma, Veterin and Lamda Detergent
- Combination offers significant opportunity to generate synergies in sales and marketing, sourcing, manufacturing and distribution logistics
- Two core business units
 - **Healthcare—human health pharmaceuticals, medical devices, veterinarian products**
 - **Non-healthcare—detergents, cosmetics and organic products**
- Headquartered in Athens, Greece, the Group employs c. 1,730 people
- Market cap €1.1bn

Strategic business units


ALAPIS



ALAPIS


Alapis Group—divisional breakdown (FY 2007)

Revenues



Total: €442.5 million

EBITDA



€117.3 million

Investment highlights



Strategy implementation

Background: The Greek generics market is currently highly fragmented and underdeveloped and is ready for consolidation and significant expansion

Vision: To become the leading generics player in South Eastern Europe

Step 1
Position

Build sales and marketing infrastructure through in-licensing products from third parties and the wholesale business

Step 2
Consolidate

Acquire selective assets, consolidating the market and extracting synergies

Step 3
Sustain

Strengthen position through vertical integration into retail

Strategy (cont.)

The cornerstone of the Group's strategy is its pharmaceutical business with significant cross synergies across all business areas creating a vertically integrated platform and a "one stop shop"

Human health

- Pharma is key focus area - expansion of generic products portfolio and into new geographical markets
- Cross-selling opportunities
- Sells own generics through own wholesalers
- Strong co-marketing agreements with major pharma companies

Veterinary

- Market leadership in a concentrated market
- Partnerships with industry leaders
- Product range expansion (own branded products) and geographical expansion
- Same partners as human health operations
 - serves as reference for new business

Organic products

- Greek market currently hugely under penetrated compared to Europe
- Route to gain experience in retail business
- Acquire attractive store locations
 - potential to convert into pharmacies in future

Cosmetics & Detergents

- Expansion into private label products
- Strong relationships with established multinationals
- Sales synergies with human health
 - cosmetic products share same client base (pharmacies) as human health

Significant synergies between medical devices & diagnostics with pharma

Track record in consolidation Acquisitions since July 2007

Target	Description	Enterprise value	Implied Multiples, LTM (reported)	
			EV/Sales	EV/EBITDA
1 Pharmagora SA	Distributor of pharmaceutical products	37	0.30x	4.6x
2 A. Moisoglou SA ¹	Distributor of pharmaceutical products	3	0.20x	3.9x
3 Revold Healthcare ²	Pharmaceutical retailer	1	0.32x	1.1x
4 Biochem ³	Distributor of diagnostic products	39	1.70x	6.3x
5 Farmalex	Production/distribution of pharmaceutical products	14	na	Na
6 KP Marinopoulos	Distributor of pharmaceutical products	48	0.18x	7.0x
7 Biomodus	Manufacturer of cosmetic & natural products	0.1	0.02x	Na
8 Labomed	Distributor of medical equipment	2	0.80x	2.1x
9 Lamda Applied	Research laboratory for development of generics	1	na	Na
10 Pharmacare Ltd	Distributor of veterinary products	1	0.52x	2.19x
11 PNG Gerolymatos SA ³	Production and distribution of pharmaceuticals, cosmetics, veterinary products, medical devices	210	0.84x	6.0x
Total/Averages		356	0.54x	4.15x

Note: All figures in €m

1 Financials refer to annualised H1 2007 financials

2 Financials refer to annualised Q1 2007 financials


3 Financials refer to 2008 estimated proforma figures, assumes 100% ownership, of which a 50,66% percentage is pending the approval of the Hellenic Competition Commission

Health Division

Pharmaceuticals

Greek market overview

Pharmaceutical



Favourable market dynamics

Large market

€6.2bn in Greece¹

Robust growth

2006-11E CAGR
Pharmaceutical 6%
OTC 10%²

Fragmented sector

~400 companies out of
which only 5 have sales of
more than €100m

Comments

- Mandatory pricing set by government for originator and generics products
- Generics discount to originator products 20%
- Generics market significantly under penetrated compared to other EU countries
 - expected to reach 20% penetration by 2010 (currently 12%) of the total pharma market
- Local players lack critical mass
- To consolidate, infrastructure and balance sheet strength needs to be in place
- Customer relationships critical

1 Source: National Pharmaceuticals Organisation (EOF)

2 Source: Medical Device Outlook – Greece – Espicom Business Intelligence, QIII 2006


Greek market overview (cont.)

Pharmaceutical

Greek Pharmaceutical market


Total size: €6.2 billion

By type




■ Prescription ■ OTC

By source



■ Imports ■ Domestic production

By status



■ Branded products ■ Generics

Source: Business Monitor International, EFPIA


Greek market overview (cont.)

Pharmaceutical

Greek regulatory framework

- Market regulated by National Pharmaceuticals Organisation (EOF)
- Prescribed medicines sold exclusively by authorised pharmacies
- Product prices mandated by Government (reference price)
 - prices apply to both off-patent and generic product
 - mandatory 20% price cut post patent expiration on both originator and generics


Price calculation for patent products



Division overview

Pharmaceutical

Pharmaceutical division



Key Categories


- Cardiology
- Cardiovascular
- Dermatology
- Haematology
- Respiratory
- Neurology
- Oncology
- Paediatrics
- Urology

Health Division

Medical Devices & Equipment

Greek market overview

Medical Devices & Equipment



Favourable market dynamics

Sizeable market

€770m in Greece

Steady growth

2007-11 CAGR
~4%

Import dominated

~95% from imports

Highly fragmented

Local market consists of small players distributing imported products

Comments

- Among the largest markets in South Eastern Europe
- Growth in line with market
- Broad range of products supplied by a large number of players
- Alapis co-markets with Gambro BCT, Given Imaging, Medicult and Sorin
- Relationships with hospitals and suppliers held by local players
- Multinationals lack relationships for direct distribution
- No competitors have sales in excess of €50m

Division overview

Medical Devices & Equipment

Exclusive Representative of medical devices & equipment

Key Products

Radiology devices

Cardiology devices

Renal care devices

Diagnostic devices, reactors

Main Partnerships

Gambro BCT

Given Imaging

Medicult

Sorin

Terumo

Toray


Health Division

Veterinary Pharmaceuticals & Pet Accessories

Market and business overview

Veterinary Pharmaceuticals & Pet Accessories

Market overview



Favourable market dynamics

Strong growth

- 10% in SE Europe
- Rapid growth in South Eastern Europe overdue
- Coming years generic products increasing important as consumers try to reduce costs

Import dominated

- Major international animal health companies
- Market dominated by major international animal health companies who utilise local companies to distribute products

Fragmented market

- Local market highly fragmented
- Few local competitors of scale
- Significant scope for consolidation

Business overview

- Local partner for leading multinational animal health companies in Greece, Romania and Bulgaria
 - partners include **Bayer** and **Pfizer**
- 78 sales representatives serving 5,000 customers
- Supplies wide spectrum of products for companion animals and livestock
- Alapis is market leader in both the €300 million Greek veterinary market and €80 million Pet accessories market (along with Pet Line 1)


Non-Health Division

**Cosmetics & Detergents,
Organic Products**

Market and business overview

Cosmetics & Detergents

Market overview



Favourable market dynamics

Large market

- Substantial market for cosmetics and detergents in South Eastern Europe
- Greece: €2.1 billion ¹
- South Eastern Europe (ex. Greece): €1.5 billion ²

Barriers to entry

- Multinationals who own majority of brands seeking to source locally to reduce costs
- Few local competitors with capabilities to service demand
- Private label market is under-developed
- Only 5.3% penetration (household care market) ³

Business overview

- Manufacturers of liquid and powder detergents for multinationals and private labels
- Multinationals: including Unilever, Henkel, Sara Lee, Ecolab and Johnson Diversey
- Private label: major supermarket chains
- High-quality low-cost manufacturing facilities
- Broad product range – approx. 150 product lines and approx. 800 product codes
- Own brand natural cosmetics based on olive oil

1 Source: Household products Euromonitor 2006


2 Source: Cosmetics and toiletries – Euromonitor reports (Greece – June 2006, Bulgaria – May 2006, and Romania – April 2006)

3 Source: Household products (market share by company) – Euromonitor database 2006

Market and business overview (cont.)

Organic products

Market overview



Favourable market dynamics

Growth drivers

- Overall growth of organic products has outperformed total food market ¹
- Increasing health awareness in Greece
- Increasing demand for organic products due to changing tastes among consumers
- Organic food under-penetrated in Greece:
 - 1–1.5% of total food market in Greece ¹; 2.5–3% in Europe ¹

Rapidly changing landscape

- Certified producers or organic products more than doubled over the last two years ¹
- Historical dominance of independent retailers
- Supermarkets are becoming increasingly important
- Wider range of organic products becoming available, e.g. cosmetics

Business overview

- Vertically integrated supplier of organic produce
 - Production
 - Wholesale/distribution
 - Retail
- Sales focused in home market (Greece)
- Strong relationships across a broad network of producers
- Products available to over 200 points of sale
- Strong brand through network of 16 "Organic Cycle" retail outlets
- Footprint in retail delivers synergies across all Alapis divisions


¹ Source: "Organic Agriculture & Products", Hellastat, April 2007, 2nd edition

Financials

Consolidated 9M Financial Results

9M 2008 REVENUES


Non-Healthcare



Healthcare



9M 2008 EBITDA

Non-Healthcare



Healthcare

Consolidated 9M Financial Results & Profit Margins




■ Revenue

■ EBITDA

■ EAT

Consolidated sales and EBITDA




EBITDA margin (%)

14.3	16.9	26.5	26.1	27.8
------	------	------	------	------

Notes:

- 1 Not proforma for 4 way merger and subsequent acquisitions
- 2 Pro forma for 4 way merger and subsequent acquisitions (as if on 1 January 2007)

Sales bridge 2007–2008E




Notes:

1 Alapis was formed in February 2007. Bar shows annualised FY 2007 sales (assuming merger as at 1 January 2007)

2 Since the merger, the group announced 9 acquisitions. Bar shows incremental annualised FY 2007 sales (assuming all acquisitions as at 1 January 2007)

3 Pro forma for FY 2007 mergers and acquisitions

EBITDA bridge 2007–2008E



Notes:

1 Alapis was formed in February 2007. Bar shows annualised FY 2007 EBITDA (assuming merger as at 1 January 2007)

2 Since the merger, the group announced 9 acquisitions. Bar shows incremental annualised FY 2007 EBITDA (assuming all acquisitions as at 1 January 2007)

3 Pro forma for FY 2007 mergers and acquisitions

Group financial statements

Balance sheet and cash flow

	Balance sheet			Cash flow	
(€m)	2006	2007	(€m)	2006	2007
Current assets	37.9	517.8	Profit before tax	(1.3)	95.4
Non-current assets	47.2	1,304.1	Operating activities	22.7	(31.6)
Other	5.0	3.9	Investing activities	(7.7)	(386.5)
Total assets	90.1	1,825.7	Financing activities	(14.6)	726.0
Current liabilities	18.5	118.2	Net increase / (decrease) in cash & equivalent	0.3	307.9
Non-current liabilities	40.5	96.0	Cash & equivalents at beginning of period	8.8	2.0
Other	0.7	0.5	Cash & equivalents – merged entities	0.0	8.2
Total liabilities	59.8	214.8	Cash & equivalents at end of period	9.1	318.0
Shareholders' equity	30.3	1,611.0			
Total liabilities & shareholders equity	90.1	1,825.7			

Investment highlights



Contacts

Chairman of BoD

Lavrentis Lavrentiadis

+3 0 213 017 5200

l.lavrentiadis@alapis.eu

CFO

John Papavassiliou

+3 0 213 017 5050

j.papavasiliou@alapis.eu

Appendix

Equity listing details


Trading symbols

ATHEX	ALAPIS
Reuters	ALAr.AT
Bloomberg	ALAPIS GA

Share price and capitalisation

Traded in the ATHEX as ALAPIS after the merger	01/06/2007
Listed in ATHEX (ex-Veterin)	2003
Outstanding shares	980,600,220
Market cap (25/11/2008)	€1,059m

Shareholder structure



Participation in indexes

FTSE/ASE 40	Dec 2007
FTSE/ASE International	Dec 2007
FTSE/ASE 20	1 st on the candidate list

Company milestones

Company milestones		
2007	May:	4-way merger between Elpharma, Lamda Detergent, Veterin and EBIK
	Jun:	Establishment of subsidiaries in Croatia, Hungary and Greece
	Jul:	Successful completion of €817m rights issue Establishment of subsidiary in Serbia
	Aug:	Acquisition of Farmalex, Paharmagora, A Moisoglou and Revold
	Sep:	Acquisition of 68.25% in Sumadijalek in Serbia
	Oct:	Establishment of subsidiaries in Slovenia and Ukraine
	Nov:	Acquisition of Biochem Diagnostics Establishment of subsidiary in Albania
	Dec:	Acquisition of (i) 49% stake in KP Marinopoulos (ii) 97.27% stake in Biodomus Standby revolving credit facility of €640m approved
2008	Feb:	Acquisition of Labomed, rest of Biodemus and Pharmalex Establishment of subsidiary in Poland
	Jun:	Announcement of share buy back program Establishment of Alapis research laboratories in US
	Sep:	EGM decision for issuance of non pre-emptive convertible bond of an amount of up to Euro 300 million
	Oct:	Acquisition of 49.337% of PNG GEROLYMATOS. Agreement for the acquisition of the rest 50.66% which is pending the approval of the Hellenic Competition Commission

Production facilities

Healthcare Division

Human Health

Pallini, Attica: (Land area: 7,500m²)

Former Farmalex plant, start of operation within 2008. Intention to become one of the biggest vertically integrated production facility for generics production in South East Europe



Veterinary & Animal Products

Aspropyrgos, Attica: (Land area: 25,500m²)

High quality production facilities.

Capacity utilisation: 30%

Production lines	Capacity annual
Large volume parenterals	1.5 million vials of 0.5lt
Small volume parenterals	5 million vials of 50ml
Powders	330 tn
Oral solutions	1 million vials of 1lt
Premixes	7,800 tn
Tablets	50 million tablets
Sprays	4 million sprays

Production facilities

Non-Healthcare Division

Detergents & Cosmetics

Atalanti:

Production capacity: 100,000 tons liquid detergents; 100,000 tons detergents powder; 25,000 tonnes raw material

50% capacity utilisation



Echedoros, Thessalonica:

Production capacity: 60,000 tons of chemical raw materials and liquid detergents

Storage capacity: 1,000m³



Sofia, Bulgaria:

Production capacity: 50,000 tons of liquid detergents, 50,000 tons detergent powder

Organic Products

Varda, Ilia: Production and standardisation unit

Egaleo, Attica: Storehouse—logistics

